AstraZeneca announced that its coronavirus vaccine, developed by Oxford University, is as much as 90% effective. The AstraZeneca candidate is likely to be less expensive than the Pfizer/BioNTech and Moderna vaccines, plus it does not need to be stored at extremely low temperatures. (The Washington Post)

The U.S. government will begin distributing Regeneron’s COVID-19 antibody treatment on Tuesday. The Food and Drug Administration issued emergency use authorization of the treatment, known as REGN-COV2, on Saturday. (Reuters)

Merck announced that it will acquire OncoImmune, a biotech based in Rockville, Md., for $425 million. In the deal, Merck obtains OncoImmune’s CD24Fc, a treatment for critically ill COVID-19 patients. (STAT)

Despite a Centers for Disease Control and Prevention warning against Thanksgiving-week travel, more than two million people were screened at U.S. airports on Friday and Saturday. Friday was the second day since the middle of March that airport screenings topped the one million mark. (Associated Press)

The U.S. has plenty of ventilators for the treatment of seriously ill COVID-19 patients, but not enough respiratory therapists, pulmonologists and critical care doctors to operate them. There are more than 37,000 highly trained critical care physicians, known as intensivists, in the U.S., but close to 50% of acute care hospitals don’t have any on staff. (The New York Times)